Search

everythinglearnresearchcommunity

for

Search:↓

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user has been using finasteride and minoxidil for nearly three years, maintaining and possibly regrowing hair despite noticing shedding and miniaturized hairs. They are considering adding another treatment due to concerns about ongoing hair loss.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

Dr. Gabel doesn't use Verteporfin because it's not FDA approved. The user is getting FUT and wants to minimize scarring and maximize hair regrowth.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.

AHK and GHK are discussed for hair growth in the crown area, with questions about side effects and safety after microneedling. Users share experiences and concerns about these treatments.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A user underwent a 3750 graft hair transplant in Turkey, initially promised 4500 grafts, and is satisfied with the results despite some concerns about donor site size and crown coverage. The user has been on medications like finasteride and minoxidil for about four months and may consider a second transplant in the future.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

A man in his 50s, who has been on Finasteride for 15 years, is considering adding a custom topical Minoxidil blend to his treatment due to recent hairline recession. He questions whether the custom blend is more effective than generic Minoxidil, expresses concerns about shedding and body hair growth, and seeks advice on application timing with styling products and whether to pursue other treatments like PRP or laser.

The user shared a four-month hair growth progress using 1mg finasteride daily, 2.5mg oral minoxidil daily, and Hims thick fix shampoo every other day. Replies include comments on photo quality and lighting, a joke about the frequency of Hims product mentions, and the original poster humorously wishing for a Hims sponsorship.

The conversation is about using RU58841 for hair loss treatment, specifically mixing it with minoxidil without propylene glycol due to an allergy. The user is considering starting with a lower concentration of RU58841 and making smaller batches to maintain efficacy.

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

The conversation is about finding a courier service to import minoxidil and topical finasteride from India to Europe due to lower prices. The user is seeking advice on reliable shipping options or alternative purchasing methods.

Bimatoprost is preferred over Latanoprost for hair growth. Users are seeking a reliable supplier for raw Bimatoprost powder to make their own topical solution.

The user is happy with their 3-month hair loss treatment progress using 1mg finasteride daily, 5% minoxidil twice daily, derma stamping 1-2 times a week, and WaterMans shampoo. They noticed improvements despite initial shedding and stopped taking creatine, which they suspect might have affected hair loss.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.